Selective FGFR2/3 Inhibitor Composition for Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FGFR inhibitors, particularly pan-FGFR inhibitors, exhibit significant toxic and side effects such as hyperphosphatemia and diarrhea due to their non-selectivity, limiting their therapeutic potential in cancer treatment.
Innovation Solution
Development of a selective FGFR2/3 inhibitor, represented by compounds of Formula (I), which includes specific aromatic and heteroaromatic rings, varying substituents, and functional groups to enhance selectivity and reduce off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If pan-FGFR inhibitors are used to treat FGFR-related cancers, then the therapeutic coverage is broad, but toxic side effects such as hyperphosphatemia and diarrhea increase
Solution Approach 1:
The patent segments the FGFR inhibitor class into selective FGFR2/3 inhibitors, separating them from pan-FGFR inhibitors. This segmentation allows the drug to target only specific FGFR subtypes (FGFR2 and FGFR3) associated with certain cancers and bone disorders, while avoiding inhibition of other FGFR subtypes that mediate normal physiological functions. The selective inhibition profile is achieved through specific molecular structure design that preferentially binds to FGFR2/3 isoforms, thereby maintaining broad therapeutic coverage for indicated diseases while reducing off-target toxic effects such as hyperphosphatemia and diarrhea.
2Object-affected harmful factors
If selective FGFR2/3 inhibitors are developed, then toxic side effects are reduced, but the therapeutic coverage for various FGFR-related cancers is limited
Solution Approach 1:
The patent applies local quality by designing the inhibitor to have different binding affinities for different FGFR subtypes. The molecular structure is optimized to exhibit high selectivity for FGFR2 and FGFR3 through specific structural features that match the binding pockets of these isoforms, while showing reduced affinity for other FGFR subtypes. This localized selectivity allows the drug to effectively treat FGFR2/3-driven cancers and bone disorders with minimal impact on other physiological pathways, achieving reduced toxicity without completely sacrificing therapeutic versatility within the target indication scope.
3Reliability
If non-covalent multi-target FGFR inhibitors are used, then clinical benefits are achieved, but the therapeutic dose is limited by inhibition of various kinases
Solution Approach 1:
The patent extracts the harmful multi-target inhibition activity from the FGFR inhibitor class by designing a selective single-subtype inhibitor. Instead of using non-covalent multi-target inhibitors that simultaneously inhibit FGFR, VEGFR, PDGFR and other kinases (which limits the therapeutic dose due to cumulative toxicity), the invention isolates the beneficial FGFR2/3 inhibition while removing the off-target kinase inhibition. This extraction of selective activity allows for higher therapeutic doses to be administered without the dose-limiting toxicities associated with multi-target inhibition, thereby improving the therapeutic window for FGFR2/3-driven diseases.
Data Source
AI summary
Provided are a compound represented by formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, an oxynitride, a solvate, a polymorph, a metabolite, an ester, a prodrug, or a pharmaceutically acceptable salt thereof. The compound has a good FGFR2/3 inhibitory effect, and can be used for treating or preventing FGFR2/3-mediated 5 disorders and diseases, and preparing drugs for treating or preventing such disorders and diseases.